Hallucinogen-Related & Inhalant-Related Disorders

Introduction

Hallucinogen-related and inhalant-related disorders fall under substance-related and addictive disorders in the DSM-5-TR. These disorders involve substances that significantly alter perception, cognition, mood, and behavior. Hallucinogens such as phencyclidine (PCP), LSD, and related compounds produce perceptual distortions, hallucinations, and dissociative experiences, whereas inhalants are volatile substances that produce rapid psychoactive effects when inhaled.

These substances can result in acute intoxication, persistent psychological disturbances, and long-term neurological damage. The DSM-5-TR classifies these disorders into use disorders, intoxication states, and specific conditions such as hallucinogen persisting perception disorder.

Phencyclidine Use Disorder

Introduction

Phencyclidine (PCP) use disorder refers to a maladaptive pattern of PCP use leading to clinically significant impairment or distress. PCP is a dissociative hallucinogen known for producing both perceptual distortions and severe behavioral disturbances, including aggression and impaired judgment.

Diagnostic Features

Individuals with PCP use disorder often display compulsive drug-seeking behavior, poor impulse control, and continued use despite harmful consequences. The disorder is marked by functional impairment in social and occupational domains, along with increased risk-taking and unpredictable behavior. Tolerance may develop, and users often underestimate the severity of their impairment.

DSM-5-TR Diagnostic Criteria

A. A problematic pattern of phencyclidine use leading to clinically significant impairment or distress, as manifested by at least two of the following, occurring within a 12-month period:

Phencyclidine is often taken in larger amounts or over a longer period than was intended.
There is a persistent desire or unsuccessful efforts to cut down or control use.
A great deal of time is spent in activities necessary to obtain, use, or recover from the substance.
Craving, or a strong desire or urge to use phencyclidine.
Recurrent use resulting in failure to fulfill major role obligations at work, school, or home.
Continued use despite having persistent or recurrent social or interpersonal problems caused or exacerbated by its effects.
Important social, occupational, or recreational activities are given up or reduced because of use.
Recurrent use in situations in which it is physically hazardous.
Use is continued despite knowledge of having a persistent physical or psychological problem likely caused or worsened by the substance.
Tolerance, as defined by either a need for markedly increased amounts or diminished effect with continued use of the same amount.

Etiology / Causes

Biological Factors:
Phencyclidine acts primarily as an NMDA receptor antagonist, disrupting glutamate neurotransmission and producing dissociative, psychotic-like, and cognitive effects. It also indirectly increases dopaminergic activity, contributing to its reinforcing properties. Chronic exposure alters neural circuits involved in judgment, impulse control, and emotional regulation, increasing the likelihood of repeated use.

Environmental and Psychological Factors:
Environmental exposure, particularly in high-risk or urban settings, plays a significant role. Peer influence, accessibility, and normalization of drug use contribute to initiation. Psychologically, traits such as impulsivity, sensation-seeking, and poor coping with stress or trauma increase vulnerability. Individuals may also use PCP to escape emotional distress or adverse life circumstances.

Risk and Prognostic Factors

Risk Factors:
Risk factors include co-occurring substance use, antisocial tendencies, exposure to violence, and underlying psychiatric conditions such as mood or psychotic disorders. Socioeconomic adversity and lack of supervision further increase susceptibility. Early initiation of substance use is also associated with more severe patterns.

Prognosis:
The course may be chronic, particularly with repeated use. Long-term outcomes include cognitive deficits, emotional dysregulation, and persistent psychotic symptoms. However, early intervention and sustained treatment can significantly improve functioning and reduce harm.

Treatment

Psychotherapeutic Interventions:
Cognitive-behavioral therapy focuses on modifying maladaptive thought patterns and behaviors associated with substance use. Motivational interviewing enhances readiness for change and treatment engagement. Behavioral therapies also help develop coping skills and relapse prevention strategies.

Clinical Management:
There are no specific pharmacological treatments for PCP dependence. Management focuses on supportive care, stabilization, and treatment of co-occurring psychiatric conditions. Long-term recovery is supported through structured rehabilitation programs and psychosocial support systems.

Other Hallucinogen Use Disorder

Introduction

This disorder involves the problematic use of hallucinogens other than PCP, such as LSD and psilocybin. These substances primarily affect perception and cognition, leading to altered sensory experiences and emotional states.

Diagnostic Features

Individuals exhibit recurrent use despite adverse consequences, impaired functioning, and difficulty controlling intake. The disorder is often associated with psychological dependence, though physical dependence is less prominent compared to other substances.

DSM-5-TR Diagnostic Criteria

A. A problematic pattern of hallucinogen (other than phencyclidine) use leading to clinically significant impairment or distress, as manifested by at least two of the following, occurring within a 12-month period:

The substance is often taken in larger amounts or over a longer period than intended.
Persistent desire or unsuccessful efforts to cut down or control use.
A great deal of time is spent obtaining, using, or recovering from use.
Craving or strong desire to use.
Recurrent use resulting in failure to fulfill obligations.
Continued use despite social or interpersonal problems.
Important activities given up.
Use in hazardous situations.
Continued use despite knowledge of harm.
Tolerance.

Etiology / Causes

Biological Factors:
These substances act primarily on serotonin (5-HT2A) receptors, altering sensory perception and cognitive processing. Neurobiological sensitivity to these effects, along with genetic predisposition, influences the likelihood of repeated use.

Environmental Factors:
Cultural acceptance in certain groups, peer influence, and curiosity about altered states of consciousness contribute to experimentation. Psychological distress, identity exploration, and desire for novel experiences may further reinforce use patterns.

Risk and Prognostic Factors

Risk Factors:
Adolescents and young adults are at higher risk due to experimentation and peer influence. Personality traits such as openness to experience and sensation-seeking also increase vulnerability.

Prognosis:
While many individuals do not develop chronic dependence, repeated use may lead to psychological disturbances, including anxiety and perceptual changes. Prognosis is generally better compared to other substance use disorders if use is discontinued early.

Treatment

Psychological Interventions:
Cognitive-behavioral therapy helps individuals understand triggers and develop healthier coping mechanisms. Psychoeducation plays a key role in preventing recurrence.

Supportive Care:
Treatment also includes managing co-occurring mental health conditions and promoting lifestyle changes. Strong social support and structured environments improve recovery outcomes.

Phencyclidine Intoxication

Introduction

Phencyclidine intoxication refers to the acute effects following recent PCP use, often involving severe behavioral disturbances and physiological changes.

Diagnostic Features

It is marked by agitation, aggression, impaired judgment, and dissociative experiences. Individuals may appear detached from reality and exhibit unpredictable or violent behavior.

DSM-5-TR Diagnostic Criteria

A. Recent use of phencyclidine.

B. Clinically significant problematic behavioral or psychological changes (e.g., belligerence, assaultiveness, impulsivity, impaired judgment).

C. Two (or more) of the following signs developing during or shortly after use:

Vertical or horizontal nystagmus
Hypertension or tachycardia
Numbness or diminished response to pain
Ataxia
Dysarthria
Muscle rigidity
Seizures or coma
Hyperacusis

D. The signs and symptoms are not attributable to another medical condition or mental disorder.

Etiology / Causes

Neurobiological Mechanisms:
Acute intoxication results from NMDA receptor blockade, leading to dissociation, sensory distortion, and impaired cognition. Increased dopaminergic activity contributes to agitation and psychotic-like symptoms.

Contextual Factors:
Dose, method of use, and environmental context significantly influence the severity of intoxication. Chaotic or stressful environments can exacerbate aggressive and paranoid reactions.

Risk and Prognostic Factors

Risk Factors:
High doses, repeated use, and co-occurring psychiatric disorders increase risk. Individuals with poor impulse control are particularly vulnerable.

Prognosis:
Symptoms usually resolve as the drug is metabolized, but severe cases may lead to injury or medical complications.

Treatment

Acute Management:
Management involves ensuring safety and placing the individual in a calm, low-stimulation environment.

Medical Intervention:
Benzodiazepines are used to manage agitation and seizures. Severe cases may require hospitalization and intensive monitoring.

Other Hallucinogen Intoxication

Introduction

This condition refers to acute intoxication from hallucinogens other than PCP, typically involving perceptual distortions and emotional changes.

Diagnostic Features

Individuals experience hallucinations, altered perception of time and space, and emotional instability. Insight is often impaired during the episode.

DSM-5-TR Diagnostic Criteria

A. Recent use of a hallucinogen (other than phencyclidine).

B. Clinically significant problematic behavioral or psychological changes (e.g., anxiety, depression, paranoid ideation, impaired judgment).

C. Perceptual changes occurring in a state of full wakefulness and alertness.

D. Two (or more) of the following signs:

Pupillary dilation
Tachycardia
Sweating
Palpitations
Blurred vision
Tremors
Incoordination

E. The symptoms are not attributable to another condition.

Etiology / Causes

Biological Factors:
Hallucinogens act on serotonin systems, particularly 5-HT2A receptors, altering sensory processing and perception.

Environmental Factors:
The individual’s mindset and surroundings (“set and setting”) strongly shape the experience, influencing whether it is positive or distressing.

Risk and Prognostic Factors

Risk Factors:
High doses, unfamiliar environments, and pre-existing anxiety or mood disorders increase risk.

Prognosis:
Symptoms are typically short-lived, resolving as the substance is cleared, though psychological distress may persist temporarily.

Treatment

Supportive Care:
Providing reassurance and a calm environment is crucial.

Medical Care:
Sedative medications may be used if severe anxiety or agitation occurs.

Hallucinogen Persisting Perception Disorder

Introduction

This disorder involves the recurrence of perceptual disturbances after cessation of hallucinogen use.

Diagnostic Features

Individuals re-experience visual disturbances such as halos, flashes, or trails, which can be distressing and impair functioning.

DSM-5-TR Diagnostic Criteria

A. Following cessation of hallucinogen use, the re-experiencing of one or more perceptual symptoms that were experienced while intoxicated.

B. The symptoms cause clinically significant distress or impairment.

C. The symptoms are not attributable to another condition.

Etiology / Causes

Neurobiological Factors:
Persistent alterations in visual processing pathways and neurotransmitter systems are believed to underlie the condition.

Psychological Factors:
Heightened anxiety and attentional focus on symptoms may intensify the experience.

Risk and Prognostic Factors

Risk Factors:
Frequent use, high doses, and underlying anxiety disorders.

Prognosis:
Course is variable; symptoms may persist for extended periods.

Treatment

Psychological:
CBT helps individuals manage distress and reduce symptom focus.

Medication:
Pharmacological options have limited evidence but may provide relief in some cases.

Inhalant-Related Disorders

Introduction

Inhalant-related disorders involve the use of volatile substances that produce rapid psychoactive effects when inhaled.

Diagnostic Features

These substances depress the central nervous system, leading to euphoria, disinhibition, and impaired coordination. Chronic use can result in severe neurological and organ damage.

Inhalant Use Disorder

Introduction

Inhalant Use Disorder involves a pattern of repeated inhalant use leading to impairment or distress.

Diagnostic Features

Individuals show compulsive use, inability to control intake, and continued use despite harm. It is most common among adolescents due to easy availability.

DSM-5-TR Diagnostic Criteria

A. A problematic pattern of inhalant use leading to clinically significant impairment or distress, as manifested by at least two of the following within a 12-month period:

Taken in larger amounts or longer than intended
Persistent desire or unsuccessful efforts to cut down
Time spent obtaining or using
Craving
Failure to fulfill obligations
Continued use despite problems
Activities reduced
Hazardous use
Continued use despite harm
Tolerance

Etiology / Causes

Biological Factors:
Inhalants depress CNS functioning and affect neurotransmitter systems including GABA and dopamine, producing short-term euphoria and reinforcing repeated use. Chronic exposure damages neural tissue and impairs cognitive functioning.

Environmental Factors:
Easy availability, low cost, and lack of regulation make inhalants particularly accessible to adolescents. Peer influence, neglect, and lack of supervision significantly contribute to initiation and continued use.

Risk and Prognostic Factors

Risk Factors:
Young age, low socioeconomic status, family dysfunction, and early exposure to substance use increase risk.

Prognosis:
Chronic use is associated with severe neurological damage and poor outcomes, though early intervention can improve prognosis.

Treatment

Psychosocial Interventions:
CBT, family therapy, and school-based interventions address behavioral patterns and environmental influences.

Medical Management:
Treatment includes management of neurological and physical complications, along with long-term rehabilitation and monitoring.

Inhalant Intoxication

Introduction

Inhalant intoxication refers to the acute effects following recent inhalant use.

Diagnostic Features

It is characterized by CNS depression, impaired coordination, and behavioral changes such as disinhibition or apathy.

DSM-5-TR Diagnostic Criteria

A. Recent use of an inhalant.

B. Clinically significant problematic behavioral or psychological changes.

C. Two (or more) of the following:

Dizziness
Nystagmus
Incoordination
Slurred speech
Unsteady gait
Lethargy
Depressed reflexes
Psychomotor retardation
Tremor
Muscle weakness
Blurred vision or diplopia
Stupor or coma
Euphoria

D. The symptoms are not attributable to another condition.

Etiology / Causes

Biological:
Inhalants cause rapid CNS depression and reduce oxygen delivery to the brain, leading to neurological impairment.

Environmental:
Use is often driven by accessibility, curiosity, and peer influence.

Risk and Prognostic Factors

Risk Factors:
Adolescence, neglect, and lack of supervision.

Prognosis:
Repeated intoxication can lead to brain damage, organ failure, and sudden death.

Treatment

Acute:
Immediate removal from exposure and supportive medical care are essential.

Long-term:
Rehabilitation, behavioral therapy, and social support systems are critical for recovery.